Helicos BioSciences Corp. (HLCS) Sells Multiple HeliScope(TM) Sequencers to RIKEN Institute

Sep. 8, 2009 (Business Wire) — Helicos BioSciences Corporation (NASDAQ:HLCS) today announced that the RIKEN Yokohama Institute Omics Science Center (OSC) has agreed to purchase four Helicos™ Genetic Analysis Systems. The transaction represents the first multisystem sale of the Helicos system to a large genome center. Shipments are expected to take place in September, with one system remaining in Cambridge to be used in a scientific collaboration between the two parties that began last year.

RIKEN’s OSC recently received funding from the Japanese government to assume the role of the country’s primary national DNA sequencing center. As part of Japan’s renowned RIKEN, the OSC has the unifying objective of developing a multi-purpose, large-scale analysis center to elucidate molecular networks in biological systems. A major component of the national project for the RIKEN OSC is the “Cell Innovation Project”, which is aimed at understanding cell function at the molecular level using next-generation and single-molecule sequencing technologies.

In addition to the sale of systems and reagents, RIKEN and Helicos will continue a scientific collaboration that began in November 2008. The collaborative research plan is designed to enable new insights into cell biology and to explore novel methods to ultimately enable singlecell transcriptome analyses. The OSC Director, Yoshihide Hayashizaki, M.D., Ph.D., will comanage the research plan with Patrice Milos, Ph.D., Helicos Vice President and Chief Scientific Officer.

“Our relationship with the RIKEN OSC led by Dr. Hayashizaki and RIKEN’s commitment to purchase the Helicos systems demonstrates the value of Helicos technology to the scientific community,” explained Helicos President Steve Lombardi. “We’re proud to have such a prestigious institution as our first multi-system genome center customer. Their commitment is further validation of the scientific and commercial importance of single molecule sequencing.”

“The single-molecule sequencing platform developed by Helicos will help accelerate on-going progress in transcriptomics analysis at RIKEN’s OSC,” remarked Dr. Hayashizaki. “The Helicos system offers us the ability to make unbiased measurements of nucleic acids without amplification, to utilize very low starting amounts of nucleic acid, and to generate over 800 million sequences per run, providing accurate and precise measurements. These benefits of single-molecule sequencing to quantitative expression profiling, including measuring the activity of gene regulatory regions, will greatly expand our range of experimental approaches so that we can reveal more of the unknown biology of the genome to the scientific community.”

“RIKEN has been at the forefront of scientific and technological advances that have revolutionized genomic sciences,” stated Patrice Milos. “Our collaboration over the last year, culminating in this multi-unit system acquisition, once again demonstrates the innovation and vision that serves as the RIKEN hallmark. We are honored to continue our work together.”

About Helicos BioSciences

Helicos BioSciences is a life science company focused on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets. Helicos’ proprietary True Single Molecule Sequencing (tSMS)™ technology allows direct measurement of billions of strands of DNA, enabling scientists to perform experiments and ask questions never before possible. Helicos is a recipient of the $1,000 genome grant and is committed to providing scientists the tools to unlock the era of genomic medicine. The company’s corporate headquarters are located at One Kendall Square, Building 700, Cambridge, MA 02139, and its telephone number is (617) 264-1800. For more information, please visit www.helicosbio.com.

About The Omics Science Center at the RIKEN Yokohama Institute

RIKEN is a Japanese research institute that carries out high-level experimental and research work in a wide range of fields, including physics, chemistry, medical science, biology, and engineering, covering the entire range from basic research to practical applications. RIKEN was first organized in 1917 as a private research foundation and was reorganized in 2003 as an independent administrative institution under the Ministry of Education, Culture, Sports, Science and Technology. RIKEN Omics Science Center is one of 13 research centers in RIKEN and its focus is on developing genome-wide technologies and their applications. www.riken.go.jp

Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, the anticipated commercial and scientific benefits of the sale of the Helicos systems to RIKEN OSC discussed in this press release, and management’s plans, objectives and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Helicos’ control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, our ability to successfully complete and/or scale the manufacturing and commercialization process for the Helicos Genetic Analysis System; our history of operating losses and ability to achieve profitability; our ability to sustain and scale our manufacturing capabilities; the research and development spending levels of academic, clinical and governmental research institutions and pharmaceutical, biotechnology and agriculture companies who may purchase our Helicos Genetic Analysis System; our reliance on third-party suppliers; competition; changing technology and customer requirements; our ability to operate in an emerging market; market acceptance of our technology; the length of our sales and implementation cycles; our dependence on large contracts for the sale and implementation of our Helicos Genetic Analysis System; failure of our technology and products; our ability to maintain customer relationships and contracts; ethical, legal and social concerns surrounding the use of genetic information; our ability to retain our personnel and hire additional skilled personnel; our ability to manage our growth while operating with limited resources; our ability to control our operating expenses; general economic and business conditions; our ability to obtain capital when desired on favorable terms; and the volatility of the market price of our common stock. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Helicos undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Helicos, see the disclosure contained in Helicos’ public filings with the Securities and Exchange Commission.

Atheros Comunications, Inc. (ATHR) Raises Third Quarter Guidance

SANTA CLARA, CA — (Marketwire) — 09/08/09 — Atheros Communications, Inc. (NASDAQ: ATHR), a global leader in innovative technologies for wireless and wired communications, today updated its revenue and earnings guidance for its third quarter of 2009, which was previously provided on July 21, 2009. The company now expects third quarter revenue to range between $145 million and $150 million, a sequential increase of 29 to 34 percent from the company’s second quarter revenue of $112.2 million and 5 to 9 percent higher than the company’s record revenue of $138.1 million in the third quarter ended Sept. 30, 2008. The company’s previous guidance for the third quarter ending Sept. 30, 2009 was for revenue to be up 15 to 20 percent from second quarter revenue, resulting in a revenue range of $129.0 million to $134.6 million.

Atheros reports diluted earnings per share in accordance with U.S. generally accepted accounting principles (GAAP) and additionally on a non-GAAP basis. Non-GAAP financial measures exclude the effect of stock-based compensation, amortization of acquired intangible assets, the other-than-temporary impairment of long-term investments and the tax impact of these excluded items.

Non-GAAP diluted earnings per share for the third quarter are estimated to be in the range of $0.35 to $0.39. Prior expectations for the third quarter were non-GAAP diluted earnings per share of $0.29 to $0.31.

In a separate release issued today, the company announced that it has reached a definitive agreement to acquire Intellon Corporation, (NASDAQ: ITLN) in a stock and cash transaction valued at approximately $244 million, or $181 million net of cash, cash equivalents and short-term investments as of June 30, 2009. Atheros expects to close the transaction in the fourth quarter of 2009, subject to customary closing conditions including Intellon shareholder approval.

Conference Call

Atheros and Intellon will hold a joint conference call to discuss the proposed transaction at 8:30 AM Eastern Daylight Time today. To listen to the call from within the United States, please dial (877) 835-9268 approximately 10 minutes prior to the start of the call and use the Conference ID # 29349840. To listen to the call from outside the United States, please dial (706) 634-9690 approximately 10 minutes prior to the start of the call and use the Conference ID # 29349840. A taped replay will be made available approximately one hour after the conclusion of the call and will remain available for one week after the live call. To access the replay, please dial (706) 645-9291 and use the Conference ID # 29349840.

This conference call will be available via a live webcast on the investor relations section of the Atheros web site at http://www.atheros.com. Access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the web site for 6 months.

About Atheros Communications, Inc.

Atheros Communications is a global leader in innovative technologies for wireless and wired communications. Atheros combines its wireless and networking systems expertise with high-performance radio frequency (RF), mixed signal and digital semiconductor design skills to provide highly integrated chipsets that are manufactured on low-cost, standard complementary metal-oxide semiconductor (CMOS) processes. Atheros technology is used by a broad base of leading customers, including personal computer, networking equipment and consumer device manufacturers. For more information, please visit http://www.atheros.com or send an email to info@atheros.com.

This press release includes non-GAAP diluted earnings per share. This non-GAAP measure is not in accordance with, nor does it serve as an alternative for GAAP. We believe that this non-GAAP measure has limitations in that it does not reflect all of the amounts associated with our GAAP results of operations.

In calculating non-GAAP financial measures, we exclude certain items to facilitate a review of the comparability of our core operating performance on a period-to-period basis. The excluded items represent charges and gains that are primarily driven by discrete events that we do not consider to be directly related to core operating performance. We use non-GAAP financial measures to evaluate the core operating performance of our business, for comparison with forecasts and strategic plans, for calculating return on investment and for benchmarking performance externally against competitors. In addition, management’s incentive compensation is determined using these non-GAAP measures. Since we find these measures to be useful, we believe that investors benefit from seeing non-GAAP financial measures reviewed by management in addition to seeing GAAP results. We believe that these non-GAAP measures, when read in conjunction with our GAAP financials, provide useful information to investors by offering:

--  more meaningful comparability of our on-going results;
--  the ability to better identify trends in our underlying business; and
--  a way to compare our operating results against analyst financial
    models and operating results of competitors that supplement their GAAP
    results with non-GAAP financial measures.

Guidance is provided in this press release only on a non-GAAP basis due to the inherent difficulty of forecasting the timing or amount of certain items that have been excluded from the forward-looking non-GAAP measures, and a reconciliation to the comparable GAAP guidance has not been provided because certain factors that are materially significant to the Company’s ability to estimate the excluded items are not accessible or practically estimable on a forward-looking basis.

Atheros and the Atheros logo are trademarks of Atheros Communications, Inc. All other trademarks mentioned in this document are the sole property of their respective owners.

Note on Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including Atheros’ anticipated third quarter revenue, anticipated non-GAAP earnings per share, the anticipated closing of the Intellon acquisition, and the benefits to management and investors in considering non-GAAP financial measures, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, including, but not limited to the impacts of general economic conditions, competition, whether Atheros is successful in marketing and selling its products, whether the proposed acquisition of Intellon will successfully close in the fourth quarter or at all and other risks detailed in Atheros’ Annual Report on Form 10-K for the year ended Dec. 31, 2008 and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2009, as filed with the Securities and Exchange Commission (the SEC), and in other reports filed with the SEC by Atheros from time to time. These forward-looking statements speak only as of the date hereof. Atheros disclaims any obligation to update these forward-looking statements.

Important Additional Information and Where You Can Find It

In connection with the proposed transaction, Atheros will file a Registration Statement on Form S-4 containing a proxy statement/prospectus and other documents concerning the proposed acquisition with the Securities and Exchange Commission (the SEC). Investors and security holders are urged to read the proxy statement/prospectus when it becomes available and other relevant documents filed with the SEC regarding the proposed transaction because they will contain important information. Investors and security holders may obtain a free copy of the proxy statement/prospectus (when it is available) and other documents filed by Atheros and Intellon with the SEC at the SEC’s web site at http://www.sec.gov. The proxy statement/prospectus (when available) and other documents filed with the SEC may also be obtained for free by contacting Atheros Investor Relations by e-mail at ir@atheros.com or by telephone at (408) 830-5672 or by contacting Intellon Investor Relations by e-mail at suzanne@blueshirtgroup.com or by telephone at (415) 217-7722.

Atheros, Intellon, and their respective directors, executive officers, certain members of management and certain employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Additional information concerning Atheros’ directors and executive officers is set forth in Atheros’ Proxy Statement for its 2009 Annual Meeting of Stockholders, which was filed with the SEC on April 6, 2009. Additional information concerning Intellon’s directors and executive officers is set forth in Intellon’s Proxy Statement for its 2009 Annual Meeting of Stockholders, which was filed with the SEC on April 28, 2009. These documents are available free of charge at the SEC’s web site at www.sec.gov or by going to, respectively, Atheros’ Investors page on its corporate website at www.atheros.com and Intellon’s Investor Relations page on its corporate website at www.Intellon.com. Additional information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of proxies in connection with the proposed transaction, and a description of their direct and indirect interests in the proposed transaction, which may differ from the interests of Atheros or Intellon stockholders generally will be set forth in the proxy statement/prospectus when it is filed with the SEC.

Contacts:
David Allen
Atheros Communications
408-830-5762
david.allen@atheros.com

Jack Lazar
Atheros Communications
408-773-5200
jack.lazar@atheros.com

Opexa Therapeutics, Inc. (OPXA) Reports Additional Favorable Data with Tovaxin(R)

Sep. 8, 2009 (Business Wire) — Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing Tovaxin^®, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced results from further analysis of the double-blind, placebo-controlled, 52-week Phase IIb TERMS clinical study of 150 patients with Relapsing Remitting MS (RRMS). This analysis evaluated patients with an annualized relapse rate of one or greater at study entry (ARR≥1). More than 83% of the Tovaxin-treated group (n=85) remained relapse free at one year and the annualized relapse rate after treatment decreased to 0.20, a 42% reduction compared to placebo.

The results of this expanded analysis confirm those found in the previously-reported per-protocol analysis of patients in the TERMS study with ARR>1. This post-hoc analysis which represents 86% of the total patient population in the TERMS study was conducted to evaluate Tovaxin treatment among study patients with the same baseline disease activity that is being targeted for inclusion in the forthcoming Phase IIb study. Along with a marked reduction in relapses, 73% of the Tovaxin-treated patients with ARR≥1 showed stabilization or improvement in MS disability, including 16.5% with a sustained improvement in the Expanded Disability Status Scale (EDSS) of at least one full point. On MRI, the Tovaxin-treated group also demonstrated a reduction in brain atrophy and fewer inflammatory brain lesions that progressed to “black holes,” as compared to the placebo-treated group. Treatment with Tovaxin was well tolerated, with no serious adverse events reported in any Tovaxin-treated patient.

“The expanded analysis represents the MS patient population with active relapsing-remitting disease planned for recruitment into the next Phase IIb trial of Tovaxin,” stated Dawn McGuire, MD, a board certified neurologist and a member of Opexa’s Clinical Advisory Board. “Clinical benefits include not only reduction in relapses, but a surprising reversal of disability in over 16% of Tovaxin-treated patients. Along with MRI data suggesting a reduction in neuronal cell loss, these results raise the possibility that Tovaxin-treatment may have neuroprotective as well as disease-modifying effects. Tovaxin’s favorable safety profile and these early efficacy signals strongly support moving forward with a confirmatory Phase IIb trial.”

Tovaxin is a personalized T-cell vaccine based on a patient’s individual immunologic profile. Detailed immunology data analysis from the TERMS trial indicate that Tovaxin can successfully induce changes in T-cell reactivity to all three targeted myelin antigens implicated in the autoimmune attacks causing neurologic damage in MS. These changes appear epitope-specific, are sustained for 6 months or more, and match each patient’s Tovaxin formulation. Tovaxin is not broadly immunosuppressive, an important feature of its favorable safety profile.

“From an immunology perspective, the data generated thus far from the TERMS trial, from thousands of patient samples, appear to correlate nicely with the putative mechanism of action for Tovaxin. While additional analyses are still in progress, we are also seeing early associations between depletion of myelin reactive T-cells and favorable clinical outcomes,” commented Dr. McGuire.

About Opexa

Opexa Therapeutics, Inc. is dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases. The Company’s leading therapy, Tovaxin^®, is an individualized cellular immunotherapy treatment in Phase IIb clinical development for multiple sclerosis (MS). Tovaxin is derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin, believed to be a primary cause of MS attacks and nervous system damage.

For more information visit the Opexa Therapeutics website at www.opexatherapeutics.com.

Cautionary Statement Relating to Forward – Looking Information for the Purpose of “Safe Harbor” Provisions of the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial payments, returns, royalties, performance and position, management’s strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of third party development and commercialization efforts with respect to products covered by intellectual property rights transferred by the Company, the success of third party patent prosecution efforts with respect to such products, the ability of the Company to enter into and benefit from a partnering arrangement for the Company’s product candidate, Tovaxin, on reasonably satisfactory terms (if at all), and our dependence (if partnered) on the resources and abilities of any partner for the further development of Tovaxin, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of developing a marketable product, our ability to raise additional capital to continue our treatment development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in our filings with the Securities and Exchange Commission. We assume no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.

Biogen Idec Announces Proposal to Acquire All Outstanding Shares of Facet (FACT) for $14.50 per Share in Cash

Sep. 4, 2009 (Business Wire) — Biogen Idec Inc. (NASDAQ:BIIB) today announced that it has submitted a proposal to the Board of Directors of Facet Biotech Corporation (NASDAQ:FACT) to acquire all of the outstanding shares of Facet for $14.50 per share in cash. The all-cash offer represents a premium of approximately 64% over the closing price of Facet’s common stock on September 3, 2009.

In a letter to Facet’s Board of Directors, Biogen Idec’s President and Chief Executive Officer James C. Mullen stated that Biogen Idec believes the transaction makes compelling business sense for both companies and is in the best interests of their respective shareholders. The letter underscored that the $14.50 per share, all-cash offer represents an extremely attractive opportunity for Facet’s shareholders to realize today the future value of their company. Mr. Mullen also stated that Biogen Idec believes the transaction would enable the important multiple sclerosis and solid tumor clinical programs that the companies have been working on in collaboration for nearly four years to have the best chance of reaching the market and improving patients’ lives.

Biogen Idec and Facet have been working together since 2005 under a collaboration agreement pursuant to which they have been jointly developing daclizumab for the treatment of relapsing multiple sclerosis and volociximab (M200) for the treatment of solid tumors.

Biogen Idec’s proposal is not subject to any financing contingency or approval by Biogen Idec shareholders. Biogen Idec has asked to meet with the Facet Board and its advisors and stated that it is prepared to commit all necessary resources to complete a transaction expeditiously.

Biogen Idec has engaged Leerink Swann LLC as financial advisor and Wachtell, Lipton, Rosen & Katz as legal counsel in connection with the proposed transaction.

Biogen Idec’s interest in acquiring Facet was first conveyed on August 17, 2009 by Mr. Mullen to Faheem Hasnain, President and Chief Executive Officer of Facet. That interest was confirmed in a letter sent to Mr. Hasnain and the Board of Directors of Facet on August 21 proposing a purchase price of $15.00 per share. The August 21 letter stated that it was very important to Biogen Idec that Facet not undertake any material commercial or strategic transactions prior to the consummation of a transaction with Biogen Idec. On August 28, Facet announced a collaboration with Trubion Pharmaceuticals, which Biogen Idec believes reduces the value of Facet, as apparently do Facet’s investors, as evidenced by the 22% reduction in Facet’s stock price since announcing the Trubion collaboration.

As a result, a revised proposal to acquire Facet for $14.50 per share was conveyed to Mr. Hasnain in a letter sent to Facet’s Board of Directors on September 4, 2009. The full text of the letter follows:

September 4, 2009

Facet Biotech Corporation

Board of Directors

c/o Faheem Hasnain, President and Chief Executive Officer

1500 Seaport Boulevard

Redwood City, CA 94063

Dear Faheem:

We are deeply disappointed Facet chose to announce a collaboration with Trubion on the day you and I were scheduled to discuss Biogen Idec’s all-cash proposal to acquire Facet, which you rejected on August 25.

Moreover, the timing of the Trubion collaboration follows a sequence of events that suggest you have no interest in having a bona fide discussion with us about a combination of our two companies. As we have stated, we believe such a combination makes compelling business sense for both of our companies and is in the best interests of our respective shareholders.

• On August 17, you and I spoke and I proposed various alternatives to working together including combining our two companies. On that call, we agreed to speak again later that week.
• On August 20, you and I spoke and I conveyed Biogen Idec’s interest in acquiring Facet for $15 per share in cash.
• On August 21, I sent a letter to you and Facet’s Board of Directors stating Biogen Idec’s proposal to purchase Facet for $15 per share in cash. Our letter included the statement that “our offer assumes, and it is very important to Biogen Idec, that Facet does not undertake any material commercial or strategic transactions between now and the consummation of this transaction,” which reiterated what I communicated to you on our August 17 phone call. The Trubion collaboration is an example of such a transaction.
• On August 25, you sent us a response rejecting our proposal and suggested we speak on August 28. Notwithstanding that agreement to speak, Facet announced the collaboration with Trubion prior to our call.

Accordingly, we have decided to disclose publicly our interest in pursuing a business combination with Facet. We believe your collaboration with Trubion reduces Facet’s value, as apparently do Facet’s investors, as evidenced by the 22% reduction in Facet’s stock price since announcing the Trubion collaboration. As a result, we are lowering the price we are offering to acquire Facet.

We are proposing to acquire Facet for $14.50 per share in cash, which represents a premium of approximately 64% over the closing price of Facet’s common stock on September 3, 2009.

The price Biogen Idec is proposing represents an extremely attractive opportunity for Facet’s shareholders to realize today the future value of your company. In addition, we believe this transaction will enable the important multiple sclerosis and solid tumor clinical programs that we have been working on in collaboration for nearly four years to have the best chance of reaching the market and improving patients’ lives.

Biogen Idec has engaged Leerink Swann LLC as financial advisor and Wachtell, Lipton, Rosen & Katz as legal counsel to assist us in completing this transaction. Our offer would not be subject to approval by the shareholders of Biogen Idec and is not subject to any financing contingency. We do not foresee any regulatory or other impediment to closing. Any definitive transaction documentation will be subject to the approval of our Board of Directors and would contain conditions completely customary for a transaction of this nature.

We and our advisors are prepared to meet with you and your advisors to answer any questions you may have about our offer. We would like to complete a transaction expeditiously and we are prepared to commit all necessary resources to achieve this goal.

If you are interested in negotiating a transaction, please call me as soon as possible.

Sincerely,

James C. Mullen

President and Chief Executive Officer

About Biogen Idec

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.

Statement on Cautionary Factors

This announcement is neither an offer to purchase nor a solicitation of an offer to sell securities of Facet. Subject to future developments, additional documents regarding a transaction with Facet may be filed with the Securities and Exchange Commission (the “Commission”) and, if and when available, would be accessible for free at the Commission’s website at www.sec.gov. Investors and security holders are urged to read such disclosure documents, if and when they become available, because they will contain important information. The disclosure documents may also be obtained for free from Biogen Idec, if and when available, by directing a request to Biogen Idec Inc., 14 Cambridge Center, Cambridge, MA 02142 Attention: Investor Relations.

No assurance can be given that the proposed transaction described in this press release will be successfully completed, or completed on the terms proposed or any particular schedule, that the proposed transaction will not incur delays in obtaining any approvals required for a transaction or that we will realize the anticipated benefits of any proposed transaction.

Any statements made in this press release that are not statements of historical fact, including statements about our beliefs and expectations, including the proposed acquisition of Facet, are forward-looking statements within the meaning of the federal securities laws and should be evaluated as such. Forward-looking statements include statements that may relate to our plans, objectives, strategies, goals, future events, future revenues or performance, and other information that is not historical information. These forward-looking statements may be identified by words such as “anticipate,” “expect,” “suggest,” “plan,” “believe,” “intend,” “estimate,” “target,” “project,” “could,” “should,” “may,” “will,” “would,” “continue,” “forecast,” and other similar expressions.

Although we believe that these forward-looking statements and projections are based on reasonable assumptions at the time they are made, you should be aware that many factors could cause actual results or events to differ materially from those expressed in the forward-looking statements and projections. Factors that may materially affect such forward-looking statements include: our ability to successfully complete any proposed transaction or realize the anticipated benefits of a transaction; delays in obtaining any approvals required for the transaction, or an inability to obtain them on the terms proposed or on the anticipated schedule; and other factors described generally in Biogen Idec’s periodic reports filed with the Commission. Forward-looking statements, like all statements in this press release, speak only as of the date of this press release (unless another date is indicated). Unless required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.

Jazz Pharmaceuticals to Present at Two Upcoming Investor Conferences

PALO ALTO, Calif., Sept. 3 /PRNewswire-FirstCall/ — Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that company management will present a corporate overview at two upcoming investor conferences.

Robert M. Myers, President of Jazz Pharmaceuticals, will speak at the Rodman & Renshaw Annual Global Investment Conference on Thursday, September 10, 2009 at 3:15 p.m. EDT at the Palace Hotel in New York City.

Bruce C. Cozadd, Chairman and CEO of Jazz Pharmaceuticals, will speak at the NewsMakers in the Biotech Industry Conference on Wednesday, September 16, 2009 at 9:00 a.m. EDT, at the Millennium Broadway Hotel in New York City.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry. For further information please see www.jazzpharmaceuticals.com.

LTX-Credence Corp. (LTXC) Announces Fourth Quarter and Fiscal Year Results

MILPITAS, Calif., Sept. 3, 2009 (GLOBE NEWSWIRE) — LTX-Credence Corporation (Nasdaq:LTXC), a global provider of focused, cost-optimized ATE solutions, today announced financial results for its fourth quarter and fiscal year ended July 31, 2009.

Exceeding the high end of guidance, sales for the 2009 fourth fiscal quarter were $35,176,000, up 43% from the prior quarter. Net loss for the quarter was $(9,622,000), or $(0.08) per share on a GAAP basis. Excluding the net gain on the liquidation of a subsidiary and other merger related charges totaling $(3,518,000), and amortization of purchased intangibles of $4,112,000, the net loss for the quarter was $(9,028,000), or $(0.07) per share on a non-GAAP basis.

For the twelve-month period ended July 31, 2009, sales were $137,378,000. Net loss was $(137,332,000), or $(1.13) per share on a GAAP basis. Excluding the net impact of merger related charges and other special items totaling $47,365,000, and amortization of purchased intangibles of $15,967,000, the net loss for the year was $(74,000,000), or $(0.61) per share on a non-GAAP basis.

Dave Tacelli, chief executive officer and president, commented, “Our fourth quarter sales were stronger than we had expected and represents significant improvement over our third quarter results. We believe our business has moved off the cycle bottom and continued growth is expected in our 2010 first fiscal quarter, a quarter in which we expect to return to generating positive EBITDA. With the integration efforts complete, and as we start our new fiscal year, the focus for LTXC is growth within existing customers and gaining share with new customers in specific market segments where we can bring differentiating capability that delivers the lowest cost of test.”

First Quarter Fiscal 2010 Outlook

For the quarter ending October 31, 2009, revenue is expected to be in the range of $40 million to $42 million, a sequential increase of approximately 14% to 19% from the 2009 fourth fiscal quarter. The non-GAAP net loss is expected to be in the range of $(0.05) to $(0.03) per share, assuming 128 million shares outstanding. The non-GAAP net loss guidance excludes the effect of the amortization of purchased intangibles of $2.7 million.

The Company will conduct a conference call today, September 3, 2009, at 10:00 AM EDT to discuss this release. The conference call will be simulcast via the LTX-Credence web site (www.ltx-credence.com). Audio replays of the call can be heard through October 2, 2009 via telephone by dialing 888.286.8010, pass code 53284880 or by visiting our web site at www.ltx-credence.com.

Information About Non-GAAP Measures

Due to the merger and the current economic conditions, LTX-Credence will supplement its GAAP financial results by providing non-GAAP measures to evaluate the operating performance of the Company. Non-GAAP net loss for the quarter ended July 31, 2009 excludes the net impact of merger-related and other charges, and amortization of purchased intangibles. Management finds the non-GAAP information to be useful for internal comparison to historical operating results as well as to the operating results of its competitors, and believes that this information would be useful to investors for the same purposes. A reconciliation between the Company’s GAAP and non-GAAP results is provided in the attached tables. Readers are reminded that non-GAAP information is merely a supplement to, and not a replacement for, GAAP financial measures.

Safe Harbor for Forward-Looking Statements

Statements in this release regarding guidance for LTX-Credence’s first fiscal quarter and the merger between LTX Corporation and Credence Systems Corporation completed on August 29, 2008, including the financial guidance on revenue, net loss and loss per share, improvement of the business model, reduction of break-even, the status of merger integration activities, product developments, potential customer expansion and any other statements about management’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing “believes,” “anticipates,” “plans,” “expects,” “may,” “will,” “would,” “intends,” “estimates” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: the ability to successfully integrate LTX’s and Credence’s operations and employees; current weak worldwide economic conditions; the ability to realize anticipated synergies and cost savings; the risk of fluctuations in sales and operating results; risks related to the timely development of new products, options and software applications and the other factors described in LTX’s Annual Report on Form 10-K for the fiscal year ended July 31, 2008 and Credence’s Annual Report on Form 10-K for the fiscal year ended November 3, 2007 and LTX-Credence’s most recent Quarterly Report on Form 10-Q each filed with the SEC. LTX-Credence disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About LTX-Credence Corporation

LTX-Credence is a global provider of focused, cost-optimized ATE solutions designed to enable customers to implement best-in-class test strategies to maximize their profitability. LTX-Credence addresses the broad, divergent test requirements of the wireless, computing, automotive and entertainment market segments, offering a comprehensive portfolio of technologies, the largest installed base in the Asia-Pacific region, and a global network of strategically deployed applications and support resources. Additional information can be found at www.ltx-credence.com.

LTX-Credence is a trademark of LTX-Credence Corporation.

All other trademarks are the property of their respective owners.

UQM Technologies, Inc. (UQM) and BorgWarner Collaborate on Electric Powertrain Systems

Sep. 3, 2009 (Business Wire) — UQM TECHNOLOGIES, INC. (NYSE Amex:UQM), a developer of alternative energy technologies, announced today that it is collaborating with BorgWarner (NYSE:BWA) on electric powertrain products for all-electric and hybrid-electric passenger automobiles. Initially, the companies are working together to integrate UQM Technologies’ PowerPhase^® electric propulsion system with BorgWarner’s 31-03 eGearDrive™ transmission for the all-electric CODA front-wheel drive five-passenger sedan, scheduled for introduction in the California market in mid-2010.

The UQM^® PowerPhase^® electric propulsion system has a peak power rating of 100 kW (134 horsepower) and a continuous power rating of 45 kW (60 horsepower). It delivers peak torque of 300 Nm (221 ft-lbs) and continuous torque of 160 Nm (118 ft-lbs). With a diameter of only 280 mm (11 inches) and a weight of 46 kg (102 lbs), this motor will fit easily in a wide range of passenger vehicles, including subcompacts. The system also features optimized four-quadrant performance, dynamic torque, speed and voltage control, and system energy efficiency of over 90 percent across a substantial portion of its power curve.

The BorgWarner 31-03 eGearDrive™ transmission is ideally suited for mid-range electric vehicles on either front-wheel drive or rear-wheel drive transverse driveline applications. The single-speed 31-03 uses a unique flange and coupling for adaptation to the PowerPhase^® motor housing to accommodate input shaft speeds of up to 14,000 rpm with a wide range of reduction ratios and very high operating efficiency. The 31-03 is also available with an optional ePark feature, an electronically actuated park lock system.

An electric powertrain consisting of a UQM^® PowerPhase^® electric propulsion system mated with the BorgWarner 31-03 eGearDrive™ transmission provides a compact and torque-dense package, delivering nearly 2,000 Nm (1,500 ft-lbs) of torque with a gear ratio of approximately 6.5 to 1. The package will propel a mid-size passenger vehicle at highway speeds with economical, high powertrain efficiency.

“Collaborating with suppliers such as UQM Technologies will allow us to broaden the reach of our high efficiency, purpose-built electric drive transmissions, accelerating vehicle integration for fast-to-market implementation,” said John Sanderson, President and General Manager, BorgWarner Drivetrain Systems. “We believe the pairing of our high efficiency transmission with UQM Technologies’ high performance electric propulsion systems present an extraordinary performance and value proposition to vehicle makers.”

“We are pleased to collaborate with BorgWarner, a world leader in powertrain technologies, to offer vehicle makers a turn-key electric powertrain that delivers exceptional vehicle performance at high operating efficiencies,” said William G. Rankin, UQM Technologies’ President and Chief Executive Officer. “BorgWarner’s global presence will bring a higher level of visibility to our electric propulsion system products.”

Auburn Hills, Michigan-based BorgWarner Inc. is a product leader in highly engineered components and systems for vehicle powertrain applications worldwide. The FORTUNE 500 company operates manufacturing and technical facilities in 60 locations in 18 countries. Customers include VW/Audi, Ford, Toyota, Renault/Nissan, General Motors, Hyundai/Kia, Daimler, Chrysler, Fiat, BMW, Honda, John Deere, PSA, and MAN. The Internet address for BorgWarner is: http://www.borgwarner.com.

UQM Technologies, Inc. is a developer and manufacturer of power dense, high efficiency electric motors, generators and power electronic controllers for the automotive, aerospace, military and industrial markets. A major emphasis of the Company is developing products for the alternative energy technologies sector including propulsion systems for electric, hybrid electric, plug-in hybrid electric and fuel cell electric vehicles, under-the-hood power accessories and other vehicle auxiliaries and distributed power generation applications. The Company’s headquarters, engineering and product development center, and motor manufacturing operation are located in Frederick, Colorado. For more information on the Company, please visit its worldwide website at www.uqm.com.

This Release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. These statements appear in a number of places in this Release and include statements regarding our plans, beliefs or current expectations, including those plans, beliefs and expectations of our officers and directors with respect to, among other things the development of markets for our products and the adequacy of our cash balances and liquidity to meet future operating needs. Important Risk Factors that could cause actual results to differ from those contained in the forward-looking statements are contained in our Form 10-Q filed July 30, 2009, which is available through our website at www.uqm.com or at www.sec.gov.

Curis, Inc. (CRIS) Announces GDC-0449 Phase I Clinical Data Published in New England Journal of Medicine

Sep. 3, 2009 (Business Wire) — Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines for cancer treatment, today announced that two publications describing clinical data generated with GDC-0449 were published in the current edition of The New England Journal of Medicine (NEJM). The first publication, entitled “Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma,” provides an overview of the Phase I data for the 33 basal cell carcinoma (BCC) patients treated in this study. The second paper is a case study entitled “Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449,” which provides an overview of the treatment of a single adult medulloblastoma patient with GDC-0449.

“The data published by this distinguished journal build upon the existing body of evidence and provide further support for the belief that aberrant Hedgehog signaling is strongly implicated in solid tumors such as basal cell carcinoma and medulloblastoma,” said Curis President and CEO Dan Passeri. “The ongoing pivotal Phase II clinical trial of GDC-0449 in advanced BCC being conducted by our collaborator Genentech is progressing, and if the trial is successful, may serve as the basis for a future new drug application submission by Genentech. We are also hopeful that Genentech’s ongoing Phase II clinical trials of GDC-0449 in metastatic colorectal cancer and advanced ovarian cancer patients will yield promising data supporting the use of GDC-0449 for ligand-driven cancers.”

Phase I BCC Publication

The publication entitled “Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma” provides efficacy, safety, pharmacokinetic and pharmacodynamic data summaries of the 33 BCC patients treated in the Phase I clinical trial.

Efficacy

In 18 patients with metastatic BCC, 8 patients had confirmed partial responses (7 by RECIST and 1 by clinical assessment), 1 patient had an unconfirmed partial response by RECIST, 7 patients had stable disease as a best response and 2 patients had progressive disease. RECIST provides standard parameters to be used when documenting patient response for solid tumors. The overall response rate was 50% (9 partial responses out of the 18 metastatic BCC patients in the study).

In 15 patients with clinically evaluable locally advanced BCC, 2 patients had complete clinical responses, 7 patients had partial responses, 4 patients had stable disease as the best response and 2 patients had progressive disease. The overall response rate was 60% (2 complete responses plus 7 partial responses out of the 15 locally advanced BCC patients in the study).

At the time of the data cut-off for the paper, the median time on study and the median duration of response for these patients was 9.8 and 8.8 months, respectively, with 19 patients still on study.

Safety Summary

In the Phase I study of GDC-0449, no Grade 5 adverse events were observed and there was a single Grade 4 adverse event that was not determined to be related to the study drug. The following Grade 3 adverse events were seen: fatigue (n=4), hyponatremia (n=2), weight loss (n=2), dyspnea (n=2), and one patient each with muscle spasms, atrial fibrillation, aspiration, back pain, corneal abrasion, dehydration, keratitis, lymphopenia, pneumonia, urinary tract infection, a prolonged QT interval, increased serum alkaline phosphatase, and increased serum potassium. Other adverse events were mild to moderate with 11 Grade 2 adverse events that were considered to be related to GDC-0449 treatment and that included muscle spasms (n=3), dysgeusia (n=2), anorexia (n=2), weight decrease (n=2), hypocalcemia (n=1), and dyspnea (n=1).

Pharmacokinetics (PK) and Pharmacodynamics (PD)

GDC-0449 demonstrated a favorable PK and PD profile with a median steady-state plasma concentration of 16.1 micromolar. The median time to reach this steady-state level was 14 days. Dose escalation from 150 mg to 270 mg did not result in higher total plasma concentrations of GDC-0449 and as a result, Genentech has selected a daily dose of 150 mg for the ongoing Phase II clinical trials.

Medulloblastoma Patient Articles in NEJM and Science

A brief report of an adult medulloblastoma patient treated with GDC-0449 was published in the same edition of the New England Journal of Medicine and a related paper was also published today in the online edition of Science. The NEJM brief report discusses a 26-year old medulloblastoma patient who was refractory to multiple prior therapies including surgical resection followed by radiation therapy and chemotherapy. This patient was subsequently treated with GDC-0449, resulting in symptomatic improvement and rapid but transient tumor regression. The authors of this report note that it marks the first demonstration of medulloblastoma tumor regression in a patient with a Hedgehog pathway inhibitor who had significant tumor burden and extensive metastatic disease. The Science article explores the potential mechanism of resistance in this same medulloblastoma patient. The authors found that a specific mutation in Smoothened (SMO) present in the tumor after relapse had no effect on Hedgehog signaling but did disrupt the ability of GDC-0449 to bind to SMO. Since SMO is the direct molecular target of GDC-0449, its inability to effectively bind to SMO in this patient likely led to the emergence of drug resistance. This work provides the first evidence that a family of receptors, of which SMO is included, may be subject to the development of drug resistance by mutation of a region of this receptor.

The National Cancer Institute’s (NCI) Division of Cancer Treatment and Diagnosis (DCTD) is currently sponsoring a Phase I clinical trial to evaluate dose and safety of GDC-0449 in medulloblastoma patients up to 21 years of age, as well as a Phase II trial in adult patients with medulloblastoma. Details for both trials are available at ClinicalTrials.gov.

Medulloblastoma is a malignant tumor of the cerebellum and is the most common brain malignancy in children, with a median age of diagnosis of 5 years and with incidence extending into young adulthood. As in advanced BCC, aberrant activation of the Hedgehog signaling pathway is strongly implicated in the development of some medulloblastomas.

About the Curis-Genentech Collaboration

Under Curis’ ongoing collaboration agreement with Genentech, a wholly-owned member of the Roche Group, Curis granted Genentech broad intellectual property rights relating to the Hedgehog pathway, including several classes of proprietary small molecule inhibitors. Through this collaboration, GDC-0449 was discovered by Genentech and was jointly validated by the parties through a series of preclinical studies. Genentech and Roche are responsible for the clinical development and commercialization of GDC-0449. Curis is eligible to receive cash payments upon successful achievement of certain clinical development and regulatory approval milestones and royalties upon commercialization of GDC-0449. GDC-0449 is currently being developed in three Phase II clinical trials by Genentech, including a pivotal trial in advanced basal cell carcinoma and Phase II trials in metastatic colorectal cancer and advanced ovarian cancer. Through a collaborative research and development agreement (CRADA) with NCI, the molecule is also being tested in medulloblastoma, small cell lung cancer and pancreatic cancer and is expected to be tested in additional NCI-sponsored trials in other indications in the future.

About Curis, Inc.

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new medicines for cancer indications. In expanding its drug development efforts in the field of cancer through its targeted cancer drug development platform, Curis is building upon its previous experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis’ website at www.curis.com.

Cautionary Statement: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation: statements regarding the expected beneficial role of hedgehog signaling in certain cancers; plans for further testing of GDC-0449; and expectations relating to the outcomes of additional studies of GDC-0449. Forward-looking statements used in this press release may contain the words “believes”, “expects”, “anticipates”, “plans”, “seeks”, “estimates”, “will”, “may” or similar expressions. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other factors that may cause the actual results to be materially different from those indicated by such forward-looking statements including, among other things:

• Curis may experience adverse results, delays and/or failures in its internal drug development programs.
• Curis’s collaborators may experience adverse results, delays and/or failures in their strategic alliances with Curis. For example, Genentech may not be able to replicate in later trials any favorable outcomes from earlier trials of GDC-0449.
• Curis and its collaborators may experience difficulties or delays in obtaining or maintaining required regulatory approvals for products under development.
• Curis may not be able to obtain or maintain the intellectual property protection necessary for the development and commercialization of drug candidates based on its technologies.
• Curis may not be able to obtain the substantial additional funding required to conduct research and development of its drug candidates.
• Curis may experience unplanned cash requirements which could shorten the estimated period in which Curis will have cash to fund its operations and which could also adversely affect Curis’ estimated operating expenses for 2009 and beyond.
• Curis faces risks relating to its ability to enter into and maintain planned collaborations for development candidates under its targeted cancer programs, its ability to maintain its current collaborations with Genentech and Debiopharm, and the risk that any such collaborators will not perform adequately.
• Curis also faces other risk factors identified in its Annual Report on Form 10-K for the year ended December 31, 2008, its Quarterly Report for the Quarter ended June 30, 2009 and other filings that it periodically makes with the Securities and Exchange Commission.

In addition, any forward-looking statements represent the views only as of today and should not be relied upon as representing Curis’ views as of any subsequent date. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise.

Imperial Industries, Inc. (IPII) Reports Second Amendment to Its Forbearance Agreement and Credit Facility

POMPANO BEACH, Fla., Sept. 2, 2009 (GLOBE NEWSWIRE) — Imperial Industries, Inc. (Nasdaq:IPII) announced today that the Company and the assignee for the benefit of creditors of its subsidiary, Just-Rite Supply, Inc., had entered into a Second Amendment to its Forbearance Agreement with its commercial lender to extend the terms of the credit facility from August 31, 2009 to September 30, 2009. The Amendment provides for the lender’s continued funding under the credit facility, notwithstanding the Company’s and assignee’s recent non-compliance of certain terms set forth in its Amended Forbearance Agreement, subject to the Company making reductions to its existing maximum credit of $500,000 during the month of September.

There can be no assurance that the Company will be in compliance with the terms of its amended credit facility upon termination of the Forbearance Agreement, or obtain continued forbearance and funding from the Lender on terms acceptable to the Company, or that such financing will be available at all at the end of the Forbearance period.

For further information and a more complete description of the terms of the Assignment for the Benefit of Creditors and Forbearance Agreement, please refer to the Company’s Current Report on Form 8-K to be filed with the Securities Exchange Commission.

Imperial Industries, Inc., a building products company, sells products throughout the Southeastern United States with facilities in the State of Florida. The Company is engaged in the manufacturing and distribution of stucco, plaster and roofing products to building materials dealers, contractors and others through its subsidiary, Premix-Marbletite Manufacturing Co. See our website at www.imperialindustries.com for more information about the Company.

The Imperial Industries, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3041

The statements in this press release contain certain forward-looking statements, which are subject to risks and uncertainties. Such statements, including those regarding, among other things, the success of the Company’s sales and marketing efforts, improvements in productivity, the Company’s strategy and future prospects, are dependent on a number of factors, including changes in economic, business, and competitive market conditions, and availability of financing, only some of which are within the Company’s control. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in the Company’s Securities and Exchange Commission filings under “Risk Factors.” The Company assumes no obligation to update forward-looking information to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information. A more detailed discussion of risks attendant to the forward-looking statements included in this press release are set forth in the “Forward-Looking Statements” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2008, filed with the Securities and Exchange Commission (“SEC”), and in other reports already filed with the SEC.

iMergent, Inc. (IIG) Reports Fiscal Year and Fiscal Fourth Quarter 2009 Financial Results and IRS Settlement

PHOENIX, Sept. 1, 2009 (GLOBE NEWSWIRE) — iMergent, Inc. (AMEX:IIG), a leading provider of eCommerce software, site development, web hosting and search engine optimization for businesses and entrepreneurs, today reported financial results for its fiscal year and fiscal fourth quarter ended June 30, 2009. The Company also announced a settlement with the IRS related to the IRS’ audits of its income tax returns for the fiscal years ended June 30, 2005, 2006 and 2007.

Fiscal Fourth Quarter 2009 Compared to 2008

Income from operations for the fourth quarter of fiscal 2009 increased to $1,100,000 from a loss of $438,000 in the same quarter last year due in large part to the continued success of cost saving initiatives which significantly reduced our selling and marketing expenses to approximately 44% of revenue in the current quarter down from approximately 55% of revenue in the same quarter last year. Income before income tax provision for the fourth quarter of fiscal 2009 increased 53% to $2,660,000 from $1,730,000 in the same quarter last year. The income tax benefit for the fourth quarter of fiscal 2009 was $5,880,000, primarily due to our settlement with the IRS, compared to an income tax provision of $1,180,000 in the same quarter last year. Net income for the fourth quarter of fiscal 2009 was $8,540,000, or $0.74 per diluted common share, compared to net income of $554,000, or $0.05 per common share in the same quarter last year.

Product and other revenues for the fourth quarter of fiscal 2009 were $14,100,000, compared to $22,500,000 for the same quarter last year. The lower product and other revenues were a result of a 20% reduction in the number of workshops conducted during the current quarter as compared to the prior year quarter as well as a decrease in the percentage of attendees purchasing to 24% in the current quarter, compared to 31% in the prior year quarter. Commission and other revenues for the fourth quarter of fiscal 2009 decreased 20% to $5,300,000, compared to $6,600,000 for same quarter last year. Commission and other revenues are derived from commissions on sales of ancillary products by independent third-party partners as well as hosting and other revenues. The lower commission and other revenues were a result of a smaller number of leads sent to the independent third-party partners as a result of the reduction in number of previews and full workshops.

Total operating expenses decreased 38% to $18,300,000 for the fourth quarter of fiscal 2009, compared to $29,600,000 for the fourth quarter last year, primarily as a result of cost saving initiatives in the current quarter as well as conducting fewer workshops. Selling and marketing expenses as a percentage of revenue decreased to 44% for the fourth quarter of fiscal 2009 compared to 55% for the fourth quarter of fiscal 2008. The decrease is attributable to the continuation of cost savings initiatives in the current quarter which reduced our cost per direct response advertising piece which in turn decreased our advertising cost per buyer.

Cash used in operating activities was $826,000 for the fourth quarter of fiscal 2009, compared to cash provided by operating activities of $3,400,000 for the same period in fiscal 2008. As of June 30, 2009, cash and cash equivalents were $20,500,000, working capital was $16,300,000, and working capital excluding deferred revenue was $40,000,000. Total current and long-term net trade receivables were $30,800,000 as of June 30, 2009.

Year Ended June 30, 2009 Compared to 2008

Revenues for the year ended June 30, 2009 were $94,400,000 compared to $128,000,000 for the same period last year. Total operating expenses were $102,300,000, compared to $131,300,000 for the same period last year.

For the year ended June 30, 2009, net loss was $7,500,000, or $.66 per diluted common share, which included a $5,700,000 income tax provision. Net income for the year ended June 30, 2008, was $3,100,000, or $0.26 per diluted common share, which included a $3,000,000 income tax provision. Cash used in operating activities was $7,000,000 for the year ended June 30, 2009, compared to cash provided by operating activities of $10,400,000 for the same period last year.

Steven G. Mihaylo, Chief Executive Officer of iMergent, stated, “While economic conditions have been challenging this year, we maintained our focus on improving our marketing efforts to reach more highly qualified prospects, improved customer satisfaction, improved our operating efficiency, reduced costs, and expanded our product offerings to provide the tools and expertise necessary to allow our customers to compete in this competitive marketplace. In light of this challenging environment, we are pleased with the results of the past two quarters. While we expect the challenging economic conditions to continue for the next few quarters, we believe we have positioned ourselves well for a return to a more stable economic environment.”

Clint Sanderson, Senior Vice President of iMergent, added, “We are continuing to focus on the small to medium enterprise market (SME) through our Crexendo Business Solutions division. While still in the beginning stages, we are encouraged by the initial positive reaction this offering has received from both Value Added Resellers (VARs) and the end user customers. Our focus over the next three to six months will be on developing the tools necessary to allow us to scale our search engine optimization (SEO) and search engine management (SEM) offerings to a larger customer base. We are pleased with the progress made in the development of our managed network services and hosted telecom service lines. We expect to launch our hosted telecom service within the next six to nine months.”

IRS Settlement

“On August 28, 2009, we agreed to a formal settlement with the Internal Revenue Service (“IRS”) appeals office related to the audits of our income tax returns for fiscal years 2007, 2006 and 2005,” stated Jonathan R. Erickson, Chief Financial Officer of iMergent. “The decision is important as the settlement with the appeals office allows us to deduct 100% of all meals served to attendees at both our workshop and preview training sessions, which we have done historically and will continue to do. It was also agreed that our ownership change in April 2002 limited our usage of net operating losses (NOL’s) generated prior to the ownership change to offset future taxable income to $461,000 per year. As a result, we recorded a valuation allowance against these NOL’s of approximately $5,100,000 during the fiscal year ended June 30, 2009. Additionally, we were able to resolve all other outstanding issues with the IRS with no impact to the financial statements.”

“We are pleased with the outcome of the IRS settlement,” stated Steven G. Mihaylo, Chief Executive Officer of iMergent. “This settlement eliminates this uncertainty and allows us to focus our efforts on providing superior products and services to our StoresOnline and Crexendo Business Solutions customers.”

Conference Call

The company is hosting a conference call today at 1:30 p.m. PT (4:30 p.m. ET). The conference call will be broadcast live over the Internet at www.imergentinc.com. If you do not have Internet access, the telephone dial-in number is 866-673-7695 for domestic participants and 404-665-9596 for international participants. Please dial in five to ten minutes prior to the beginning of the call at 1:30 p.m. PT (4:30 p.m. ET). A telephone replay will be available two hours after the call through September 3, 2009 by dialing 800-642-1687 for domestic callers or 706-645-9291 for international callers and entering access code 95395409. Online webcast replay will be available for 90 days from the date of the call.

About iMergent

iMergent provides e-commerce solutions to entrepreneurs and businesses enabling them to market and sell their business products or ideas via the Internet. The company sells its proprietary software and training services which help users build Internet strategies to allow entrepreneurs and businesses to market and sell their products, accept online orders, analyze marketing performance and manage pricing and customers over the Internet. In addition to software and training, iMergent offers site development, web hosting and search engine optimization (SEO). iMergent, StoresOnline and Crexendo Business Solutions, Inc. are trademarks of iMergent, Inc.

Safe Harbor Statement

This press release contains forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for such forward-looking statements. The words, “believe,” “expect,” “anticipate,” “estimate,” “will” and other similar statements of expectation identify forward-looking statements. Specific forward-looking statements in this press release include information about iMergent, (1) continuing to focus on the small to medium enterprise market (SME) through its Crexendo Business Solutions division, (2) being encouraged by the initial positive reaction the SME offering has received from both Value Added Resellers (VARs) and end user customers, (3) focus over the next three to six months being on developing the tools necessary to allow iMergent to scale its search engine optimization (SEO) and search engine management (SEM) offerings to a larger customer base, (4) expecting to launch its hosted telecom service within the next six to nine months, (5) maintaining its focus on improving marketing efforts, delivering customer satisfaction, improving operating efficiencies and expanding product offerings, (6) has positioned itself well for a return to a more stable economic environment, (7) continuing to deduct 100% of the cost of meals, (8) resolving all other outstanding issues with the IRS with no impact to the financial statements and (9) providing superior products and services to our customers. You are cautioned not to place undue reliance on our forward-looking statements. We do not undertake any obligation to publicly update any forward-looking statements to reflect events, circumstances or new information after the release of this press release, or to reflect the occurrence of unanticipated events.

For a more detailed discussion of risk factors that may affect iMergent’s operations and results, please refer to the company’s Form 10-K for the year ended June 30, 2009. These forward-looking statements speak only as of the date on which such statements are made, and the company undertakes no obligation to update such forward-looking statements, except as required by law.

Ixia (XXIA) Enters into Distribution Agreement with Ingram Micro

Sep. 2, 2009 (Business Wire) — Ixia (NASDAQ: XXIA), a leading, global provider of IP performance test systems, today announced a strategic distribution agreement with Ingram Micro Inc. (NYSE: IM), the world’s largest technology distributor. Under this agreement, Ingram Micro will market and distribute Ixia’s IxChariot to its channel partners in the United States and Canada.

As companies’ networks and applications become increasingly complex, network performance becomes mission critical. Applications such as VoIP, video on demand, and intelligent enterprise applications introduce potential network bottlenecks that must be isolated and corrected. IxChariot is the industry’s leading test tool for simulating real-world applications to predict device and system performance under realistic load conditions.

“With over 6000 customers, IxChariot is the industry’s definitive standard for small-to-medium enterprise (SME) network testing,” said Atul Bhatnagar, president and CEO of Ixia. “Through Ingram Micro’s vast network, more system integrators and enterprises will be able to integrate this valuable tool into their IT networking arsenal.”

As the most flexible network assessment tool on the market, IxChariot has been used by enterprises and industry leading publications to stage numerous performance tests on networks such as wireless LANs, converged networks, and next-generation 3G networks. IxChariot has its own online user forum available at www.testtalk.net and sample test plans available at www.ixchariot.com.

“IxChariot is an excellent tool for both our resellers and their end-users,” said Eric Kohl, director, vendor management at Ingram Micro. “System integrators and VARs can use IxChariot for network assessment and planning as a value-added service to their customers, while enterprise customers can perform regular assessment and problem isolation for their networks and applications.”

About Ixia

Ixia is a leading supplier of test, measurement and service verification solutions to Internet equipment manufacturers, carriers, service providers, government agencies and enterprises. Ixia’s platform is used to test IP networking equipment of all types and sizes, with powerful and flexible test applications that handle the widest range of Internet usage – from routing and switching to converged applications traffic to validating the service quality of live networks and services. Ixia’s multiplay test solutions are acknowledged as the market leader – addressing the growing need to test voice, video, and data services and network capability under real-world conditions.

About Ingram Micro

As a vital link in the technology value chain, Ingram Micro creates sales and profitability opportunities for vendors and resellers through unique marketing programs, outsourced logistics services, technical support, financial services, and product aggregation and distribution. The company serves 150 countries and is the only broad-based global IT distributor with operations in Asia. Visit www.ingrammicro.com.

Retractable Technologies, Inc. (RVP) Acts to Reduce Annual Operating Expenses by $6 Million

Retractable Technologies, Inc. (AMEX: RVP), a leading maker of safety needle devices, continues to experience significant barriers against our efforts to establish access for sales of our products. With limited access to capital markets, we have determined that in the interest of the long-term survival of the Company, we would reorganize some of the Company’s functions, and implement staff reductions, all in order to minimize our cash expenditures and conserve our resources. We are announcing today a number of cost-cutting measures that we are implementing with the intent to reduce our cash outlays by $6,000,000 over the next twelve months.

Our President and CEO, Thomas J. Shaw, has waived $1,000,000 in future royalty payments. The five percent royalty that Retractable pays for the exclusive right to manufacture and sell the VanishPoint® products was granted for patents that Mr. Shaw developed.

Retractable reluctantly reduced its workforce by 16 percent late last week.

We will reduce the compensation of employees above a certain salary level by 10 percent effective the beginning of August.

The Company is discontinuing its matching of employees’ 401 (k) contributions effective August 1st. Matching contributions were $120,000 last year.

As circumstances change, these decisions will be reviewed.

The Company also plans to reduce inventory levels and to cut other expenses. Retractable has several new products in the “pipeline” that it plans to introduce in the coming year.

Retractable Technologies, Inc. manufacturers and markets safety medical products, principally VanishPoint® automated retraction safety syringes and blood collection devices, that virtually eliminate healthcare worker exposure to accidental needlestick injuries. These revolutionary devices use a patented friction ring mechanism that causes the contaminated needle to retract automatically, a feature that is designed to prevent both accidental needlestick injury and device reuse. Retractable also manufactures and markets Patient Safe™ syringes that are uniquely designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. Our products are distributed by various specialty and general line distributors. For more information on Retractable, visit our website at www.vanishpoint.com.

Forward-looking statements in this press release are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 and reflect our current views with respect to future events. We believe that the expectations reflected in such forward-looking statements are accurate. However, we cannot assure you that such expectations will materialize. Our actual future performance could differ materially from such statements.

Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain liquidity; our maintenance of patent protection; the impact of current litigation (as it affects our costs as well as market access and the viability of our patents); our ability to maintain favorable supplier arrangements and relationships; our ability to successfully receive royalties from Baiyin Tonsun Medical Device Co., Ltd.; the impact of dramatic increases in demand; our ability to quickly increase capacity in the event of a dramatic increase in demand; our ability to access the market; our ability to maintain or lower production costs; our ability to continue to finance research and development as well as operations and expansion of production; the increased interest of larger market players, specifically Becton Dickinson & Company, in providing devices to the safety market; and other risks and uncertainties that are detailed from time to time in the Company’s periodic reports filed with the U.S. Securities and Exchange Commission.

Novavax, Inc. (NVAX) Announces Positive Results

ROCKVILLE, Md., Sept. 1 /PRNewswire-FirstCall/ — Novavax, Inc. (Nasdaq: NVAX) announced today favorable results from a Phase II human clinical trial of its trivalent seasonal influenza virus-like particle (VLP) vaccine candidate. The vaccine was well tolerated and induced robust immune responses against all three influenza strains in the vaccine. These results continue to support the planned study in elderly adults scheduled for the fourth quarter this year and pave the way for Novavax to advance its seasonal influenza VLP vaccine into Phase III studies next year.

This Phase IIa study, which began in May of this year, was a randomized, blinded, placebo-controlled study to examine the safety and immunogenicity of different doses of Novavax’s seasonal influenza VLP vaccine candidate. The vaccine contained three VLPs (H3N2, H1N1, and B) that were matched to the strains recommended for influenza vaccines for the past flu season (2008-2009). The study enrolled 221 human subjects 18 to 49 years of age who received either placebo or VLP vaccine at doses of 15 mcg and 60 mcg per strain. Twenty additional subjects received a licensed, egg-based influenza vaccine (Fluzone(R), sanofi pasteur, USA).

Novavax’s influenza VLP vaccine candidate was well tolerated. No vaccine-related serious adverse events were reported in the study and the rate of non-serious adverse events was comparable in the vaccine and placebo groups.

The VLP vaccine also induced strong hemagglutination inhibition (HAI) antibody responses against the influenza H1N1, H3N2, and B strains. The HAI responses met the seroconversion criteria for licensure as outlined in the FDA guidance document for influenza vaccine development. Seroconversion rates (i.e., percentage of subjects with a 4-fold or higher rise in HAI titer from baseline) ranged from 81-86% for H3N2, 57-66% for H1N1, and 62-67% for B for subjects with and without existing antibody before vaccination. As seen in Novavax’s previous seasonal flu vaccine study, robust HAI responses were also observed against drifted H3N2 strains, demonstrating the potential for VLP vaccines to be cross-protective against flu viruses from different seasons without the addition of an adjuvant.

One of the main advantages of Novavax’s recombinant, cell culture based VLP technology is that it results in VLPs that are a genetic match to the flu strains of interest. It does not require live flu virus seed that has to be adapted to grow in eggs to create the egg-based vaccine. This attribute of recombinant VLPs may lead to a more efficacious vaccine against the flu strains that are circulating in the community. The results of this study provided Novavax’s first human data to support this hypothesis. The H3N2 strain that was circulating during the 2008-2009 season did not grow well in eggs; therefore, an adapted or “substitute” strain had to be used to make the egg-based influenza vaccines, including Fluzone(R), the same egg-based vaccine used in this study. Recipients of Novavax’s VLP vaccine had higher antibody responses against the H3N2 virus that was circulating in the community than recipients of Fluzone(R). The number of subjects that were studied was too small to draw definitive conclusions, but the results strongly support moving forward with larger head-to-head trials of the VLP and egg-based vaccines, the first of which is scheduled to start this Fall in elderly adults.

“The safety and immunogenicity results from this study give us confidence to move our seasonal influenza VLP vaccine candidate forward into late phase development,” said Dr. Penny Heaton, Chief Medical Officer and Vice President of Development of Novavax. “Given the immunogenicity results we saw with our VLP vaccine candidate as compared with the egg-based vaccine, we are now particularly excited to begin the larger head-to-head study in elderly adults this Fall,” Dr. Heaton said.

The results of this study are strongly supportive of accelerated development of Novavax’s pandemic influenza vaccines, including the novel H1N1 2009 influenza VLP vaccine. “We are working tirelessly with partners and governments worldwide to potentially provide H1N1 vaccine to regions without an indigenous supply,” said Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax. “The current influenza pandemic underscores the potential for Novavax’s advanced influenza vaccine technology to have significant public health impact by providing vaccine in time to those in need,” said Dr. Singhvi.

Seasonal and Pandemic Influenza

Seasonal epidemics of influenza cause an estimated 200,000 hospitalizations and 36,000 deaths in the US each year. With the H1N1 2009 influenza pandemic, US health officials are projecting an additional 30,000 to 90,000 deaths will occur during the upcoming influenza season and approximately 40% of US citizens will be infected. Because the H1N1 2009 virus is a new strain, individuals lack antibody to fight it. Good handwashing, coughing into a sleeve, and staying home when ill are some ways to prevent H1N1 flu; however, the most effective way to prevent it is through vaccination.

Globally, seasonal flu infects between 5 percent and 20 percent of the population and kills between 250,000 and 500,000 people each year. Because of the limited number of individuals with antibody against the novel H1N1 2009 virus, the World Health Organization (WHO) has projected that up to a third of the world’s population may be infected this year, with as many as 15% of those requiring hospital care.

About Novavax

Novavax is a clinical-stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches.

Forward Looking Statements

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding revenues, operating expenses, cash burn, and clinical developments and anticipated milestones are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the Company’s ability to progress any product candidates in preclinical or clinical trials; the scope, initiation, rate and progress of its preclinical studies and clinical trials and other research and development activities; clinical trial results; even if the data from preclinical studies or clinical trials is positive, the product may not prove to be safe and efficacious; regulatory approval is needed before any vaccines can be sold in or outside the US; the rate and progress of manufacturing scale-up; Novavax’s pilot plant facility is subject to validation and FDA inspections, which may result in delays and increased costs; the success of the Company’s joint ventures and licensing agreements; the Company’s ability to enter into future collaborations with industry partners and governments and the terms, timing and success of any such collaboration; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; the Company’s ability to obtain rights to technology; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; the Company’s ability to obtain adequate financing in the future through product licensing, public or private equity or debt financing or otherwise; general business conditions; competition; business abilities and judgment of personnel; and the availability of qualified personnel. Further information on the factors and risks that could affect Novavax’s business, financial conditions and results of operations, is contained in Novavax’s filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.

America’s Car-Mart, Inc. (CRMT) Reports First Quarter Earnings

BENTONVILLE, Ark., Sept. 1, 2009 (GLOBE NEWSWIRE) — America’s Car-Mart, Inc. (Nasdaq:CRMT) today announced its operating results for the first fiscal quarter ended July 31, 2009.

Highlights of first quarter operating results:

* Net income of $7.0 million ($.60 per diluted share) vs.
   $5.3 million ($.45 per diluted share) for prior year quarter
 * Active customer base increased 5% to over 44,000 during the quarter
   ended July 31, 2009
 * Strong cash flows reflected in the $13.3 million increase in Finance
   Receivables and $1.1 million in capital expenditures with only a
   $745,000 increase in debt
 * Revenue increase of 10.7% with same store revenue growth of 8.5%
 * Retail unit sales increase of 11.3%
 * Provision for credit losses of 19.5% of sales vs. 20.9% for prior
   year quarter
 * Accounts over 30 days past due of 3.5% at July 31, 2009 compared to
   3.6% at July 31, 2008
 * Net charge-offs as a percentage of average Finance Receivables
   decreased to 5.1% from 5.7% for the prior year quarter. Collections
   as a percentage of average Finance Receivables increased to 16.6%
   from 16.4%.
 * Gross margin of 44.1% of sales vs. 43.6% for prior year quarter
 * Finance Receivables growth of $13.3 million (5.8%) during the
   quarter to $244.7 million
 * Debt to equity of 18.6% and debt to finance receivables of 12.5%

For the three months ended July 31, 2009, revenues increased 10.7% to $83.8 million compared with $75.7 million in the same period of the prior year. Income for the quarter was $7.0 million or $.60 per diluted share, versus $5.3 million, or $0.45 per diluted share in the same period last year. Retail unit sales increased 11.3%, with 8,182 vehicles sold in the current quarter, compared to 7,353 in the same period last year. Same store revenue increased 8.5% for the quarter. The provision for credit losses was 19.5% of sales compared to 20.9% in the same period last year. Net charge-offs as a percentage of average finance receivables was 5.1% compared to 5.7% in the same period last year. Gross profit on vehicle sales was 44.1% for the quarter compared to 43.6% for the prior year quarter. Finance Receivables grew by $13.3 million during the quarter or 5.8%. The allowance for credit losses is 22% of Finance Receivables principal balance at both July 31, 2009 and 2008.

“We are very pleased with our first quarter results and we look forward to continuing to push for improvements as we move forward,” said William H. (“Hank”) Henderson, President and Chief Executive Officer of America’s Car-Mart. “Our top line has been positively impacted by a number of factors including 1) our focus on improving per location volume levels, especially for our newer stores, 2) better lot level execution in all areas of our business, 3) an expanding market which has resulted from credit constrictions for vehicle consumers and most of our competitors, and 4) what we believe to be a solid increase in market share for our current service areas. Our branding campaign, which we started about three years ago, is continuing to provide increased awareness for America’s Car-Mart and the superior value we bring to people looking for good, affordable basic transportation and the related financing to go with it. We anticipate the demand for our vehicles and service to continue to increase into the future.”

“The significant infrastructure investments we have made over the last few years will allow us to support higher sales volumes at existing locations and to continue our ‘grass-fire’ growth approach in adding new locations,” continued Mr. Henderson. “New locations will generate strong incremental profits and provide our talented associates with individual growth opportunities. Since the end of April we have added new dealerships in Rogers, Arkansas, Okmulgee, Oklahoma and Lebanon, Missouri and we are adding a new location in Owasso, Oklahoma this week. We are very excited about these new locations and anticipate great results from them. The 10.7% increase of our top line resulted from an 8.5% increase in same store sales and sales generated at our four new locations added since the first quarter of fiscal 2009. The negative macro economic issues have so far been positive for us as we have a very healthy balance sheet and strong cash flows, allowing us to continue to grow our customer base without the need for significant levels of debt, unlike most of our competitors. We believe that the tight consumer credit markets will continue to push more people into our markets, where they will find Car-Mart to be ‘the’ choice for their next car purchase.”

“We are so proud of our associates for the great attitude and work ethic they bring to serving our customers,” added Mr. Henderson. “Our mission is to earn the repeat business of our customers by providing quality vehicles, affordable payment terms and excellent service. Our associates are fulfilling this mission daily which is reflected in our strong operational performance. Our focus is on better cars, better underwriting and better collections with a strong infrastructure to support our lot level efforts.”

“From a financial standpoint, we continue to be extremely pleased with our results”, said Jeff Williams, Chief Financial Officer of America’s Car-Mart. “We have been able to keep our average selling price relatively flat with the prior year’s quarter and actually down 1.6% sequentially. This lower selling price not only keeps our vehicles more affordable for our customers but also provides for a higher gross margin percentage which was slightly over 44% for the quarter. In addition, even though our sales volumes were significantly higher than the prior year period, we were able to increase down-payments from 6.5% to 7.0% for the quarter. We saw strong cash flows which allowed us to grow our customer count by over 2,000 and the resulting receivable dollars by over $13 million with only a slight increase in overall debt levels. Our debt to equity and debt to finance receivables ratios of 18.6% and 12.5%, respectively, are the best in the industry and are further indicators of the strength of our operations and business model. Our collection percentages were up, our charge-off percentages down and the average percentage of finance receivables-current improved compared to the first quarter of last year. Similarly, our provision for credit losses of 19.5% as a percentage of sales is at its lowest level in several years.”

Conference Call

Management will be holding a conference call on Tuesday, September 1, 2009 at 11:00 a.m. Eastern time to discuss first quarter results. A live audio of the conference call will be accessible to the public by calling (800) 946-0706. International callers dial (719) 457-2601. Callers should dial in approximately 10 minutes before the call begins. A conference call replay will be available one hour following the call for thirty days and can be accessed by calling (888) 203-1112 (domestic) or (719) 457-0820 (international), conference call ID #4911133.

About America’s Car-Mart

America’s Car-Mart operates 96 automotive dealerships in eight states and is the largest publicly held automotive retailer in the United States focused exclusively on the “Buy Here/Pay Here” segment of the used car market. The Company emphasizes superior customer service and the building of strong personal relationships with its customers. The Company operates its dealerships primarily in small cities throughout the South-Central United States selling quality used vehicles and providing financing for substantially all of its customers. For more information on America’s Car-Mart, please visit our website at www.car-mart.com.

Included herein are forward-looking statements, including statements with respect to projected revenues and earnings per share amounts. Such forward-looking statements are based upon management’s current knowledge and assumptions. There are many factors that affect management’s view about future revenues and earnings. These factors involve risks and uncertainties that could cause actual results to differ materially from management’s present view. These factors include, without limitation, assumptions relating to unit sales, average selling prices, credit losses, gross margins, operating expenses, collection results, operational initiatives underway and economic conditions, and other risk factors described under “Forward-Looking Statements” of Item 1A of Part I of the Company’s Annual Report on Form 10-K for the fiscal year ended April 30, 2009 and its current and quarterly reports filed with or furnished to the Securities and Exchange Commission. All forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company does not undertake any obligation to update forward-looking statements.